Brain tumour (medulloblastoma)

Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline

Who can joinChildren and adults

Age5–39 years

Kind of studyObservational: no new treatment

What it testsWatches and records only

The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.

Where to go

1 hospital in India taking patients for this trial.

Tata Memorial Hospital (TMH) Parel, and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), KhargharMumbai, MaharashtraDirections ↗

Registry summary (technical)

Radiation constitutes an integral component in the management of primary brain tumors in pediatric and young adults like medulloblastoma, ependymoma, low-grade glioma, pituitary tumors, etc. A decline in neurocognitive outcomes is a multifactorial effect occurring from the primary disease as well as associated with treatments, including radiation. Since many of these tumors are highly curable, it is crucial to reduce long-term side effects, including memory loss, to improve the quality of life in these patients, leading to better rehabilitation. Radiation-induced neurocognitive deterioration i…

Sponsor: Tata Memorial Centre
NCT06779487 on ClinicalTrials.gov
Last updated on the registry 11 Apr 2025 · read by us 20 Oct 2026

Brain tumour (medulloblastoma)

Where to go

Need help reaching the trial team? Write to us.